Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Koenig – page 80

1 643 clinical trials in Bad Koenig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Koenig at a glance
1 643
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 643 trials in Bad Koenig

Open in trial search

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Study of AMG 732 injection compared to placebo in patients with moderate to severe thyroid eye disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AMG 732
  • Sponsor:Amgen Inc.

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Cardiac amyloidosis

Not recruiting

Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Novo Nordisk A/S

Urticaria chronic

Not recruiting

Study of BLU-808 tablets compared to placebo in adults with chronic inducible urticaria and chronic spontaneous urticaria

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BLU-808
  • Sponsor:Blueprint Medicines Corp.

Comparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Study of inhaled BX004 bacteriophage treatment for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa lung infection

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IHMA-2121771-1
  • Sponsor:Biomx Ltd.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Koenig

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. These studies are investigating innovative approaches for patients undergoing regular dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

Current research aims to evaluate new therapeutic interventions targeting C-reactive protein levels, a key marker of inflammation in cardiovascular disease, potentially offering new hope for dialysis patients dealing with cardiovascular complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.